Fractyl Logo

Our Company

Addressing root causes of metabolic disease—in the gut and the pancreas

We are a metabolic therapeutics company focused on pioneering new approaches for the treatment of metabolic diseases, including type 2 diabetes and obesity. Our goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of T2D and obesity. We believe there is significant clinical and economic opportunity for new approaches to achieve a major leap forward with new disease-modifying strategies that are designed to target and potentially reverse root cause pathology of these diseases.

We have assembled a mission-driven team of innovators and experts in the root causes of metabolic disease, all united in their passion to develop breakthrough therapies—the type of therapies we would want for ourselves, our family members, and our loved ones with these diseases.

Leadership

We are experts in metabolic disease.

Management Team

Harith Rajagopalan, MD, PhD Open

Harith Rajagopalan, MD, PhD

Co-founder and CEO

Jay Caplan Open

Jay Caplan

Co-Founder, President and Chief Product Officer

Lisa Davidson Open

Lisa Davidson

Chief Financial Officer

Timothy Kieffer, Ph.D. Open

Timothy Kieffer, Ph.D.

Chief Scientific Officer

Sarah Toomey Open

Sarah Toomey

General Counsel and Corporate Secretary

Jon Fitzgerald Open

Jon Fitzgerald

Vice President of Quality Assurance and Regulatory Affairs

Len Rosberg Open

Len Rosberg

Vice President of Manufacturing

Kelly White, PharmD Open

Kelly White, PharmD

Vice President of Clinical and Medical Affairs

Helmut Giersiefen, PhD Open

Helmut Giersiefen, PhD

Head of Business Development